Evidence map›Paper›PMID 42153489›Full record

ArticleJournal of diabetes investigation2026

Continuous glucose monitoring-guided management of capivasertib-associated hyperglycemia: A case series of three patients.

Hiroki Okumura, Ryotaro Bouchi, Kenju Ando, Hannah Mizuno, Hirofumi Sugimoto, Kotaro Umamoto, Noriko Kodani, Noriko Ihana-Sugiyama, Kazuo Izumi, Mitsuru Ohsugi and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hiroki OkumuraDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Ryotaro BouchiDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7664-4342
Kenju AndoDepartment of Breast and Medical Oncology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Hannah MizunoDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Hirofumi SugimotoDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Kotaro UmamotoDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Noriko KodaniDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Noriko Ihana-SugiyamaDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Kazuo IzumiDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Mitsuru OhsugiDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Kohjiro UekiDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1523-8102
Akihiko ShimomuraDepartment of Breast and Medical Oncology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Chikako ShimizuDepartment of Breast and Medical Oncology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Akiyo TanabeDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Capivasertib, an AKT inhibitor for advanced breast cancer, frequently induces hyperglycemia. We present a case series of three patients (two without pre-existing diabetes) monitored with continuous glucose monitoring. Hyperglycemia developed within 2 weeks in all cases. Continuous glucose monitoring visualized glycemic fluctuations synchronized with the "4-days-on, 3-days-off" cycle. A patient with low baseline homeostatic model assessment for β-cell function and higher insulin resistance required insulin, whereas a patient with relatively preserved insulin action was managed with oral glucose-lowering agents. These hypothesis-generating observations suggest that pretreatment metabolic assessment might assist in preliminary risk stratification.

Indexed as

Breast NeoplasmsHyperglycemiaProtein Kinase InhibitorsPyrimidinesAdultBlood GlucoseContinuous Glucose MonitoringFemaleHumansHypoglycemic AgentsMiddle AgedPrognosisBlood GlucoseHypoglycemic AgentsProtein Kinase InhibitorsPyrimidinesCapivasertibContinuous glucose monitoringHyperglycemia

Identifiers

PMID42153489
PMCPMC13399499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.